ADC Therapeutics (ADCT) Equity Income (2023 - 2024)
ADC Therapeutics' (ADCT) quarterly Equity Income came in at -$260000.0 in Q3 2024, up 81.55% year-on-year from -$143213.4 in Q4 2023, and up 56.45% quarter-over-quarter from -$597000.0 in Q2 2024.
ADC Therapeutics (ADCT) Equity Income (2023 - 2024) Analysis & Trends
ADC Therapeutics has disclosed Equity Income across 2 years of filings, most recently posting -$260000.0 for Q3 2024.
- Equity Income for Q3 2024 came in at -$260000.0, up 81.55% year-over-year; the trailing twelve-month figure through Sep 2025 was -$260000.0 (up 93.45% YoY), and the FY2023 annual result was -$6.0 million, changed N/A from the prior year.
- Equity Income came in at -$260000.0 for Q3 2024 at ADC Therapeutics, up from -$597000.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$260000.0 in Q3 2024 to a low of -$2.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -260,000.00 |
| Jun 30, 2024 | -597,000.00 |
| Mar 31, 2024 | -687,000.00 |
| Dec 31, 2023 | -2.43 Mn |
| Sep 30, 2023 | -1.41 Mn |
| Jun 30, 2023 | -767,000.00 |